(BFM Stock Exchange) – The specialist in key technologies for the manufacture of vaccines and drugs confirms its objectives after noting an improvement greater than the expectations of its financial indicators in the first half, as well as a positive trend in consumable demand. However, its action falls on the Paris Stock Exchange.

Business publications will gradually be densified from this week. This Tuesday, July 22, Sartorius Stedim Biotech unveiled before the opening of the market, its financial statements of the first half.

The table presented by the specialist in key technologies for the manufacture of vaccines and drugs, shows a frank improvement of accounts in the first half.

Strong demand for consumables

Over the first six months of the year 2025, the revenues of Sartorius Stedim Biotech increased by 8.5% in published data, and 9.4% at constant exchange rates to reach 1.49 billion euros.

The company cites a strong structural demand from customers for single -use solutions in the field of bioprocesses, which has led to an increase in turnover in all regions where the group is present.

The Americas region has increased an increase of 11 % of one year on the other, at constant exchange rates, the Europe, Middle East and Africa (EMEA) area increased by 8.7 % and turnover in the Asia/Pacific region increased by 8.1 %.

A little lower in the accounts The gross operating profit (EBITDA) rose, increased faster than turnover, from 19.3% over one year, to reach 462 million euros. SARTORIUS STEDIM Biotech attributes this improvement in its profitability to increase volumes, as well as to the enlargement of its product range and to economies of scale.

The corresponding margin thus improved by 2.8 percentage points to 31% against 28.2% over the first six months of 2024, and exceeds the expectations of Oddo BHF.

The net profit followed the same trend, progressing from 38.3% to 228 million euros, against 165 million euros over the same period the previous year.

But one in particular elements tarnish this very encouraging overall table. The group concedes that its customers remain reluctant to invest, which continued to weigh on the activity linked to equipment and systems.

“Overall, we consider the results of the second quarter to be positive. As well the turnover and the profits have exceeded the consensus, which confirms the positive trend. Although the activity of the ‘equipment’ division remains sluggish, we plan a gradual recovery in this segment in the next quarters. The recovery of the bioproching market continues, which is clearly positive and constitutes a major element of our major element of our major element of our major element and Investment file “, remarks Oddo BHF.

Confirmed perspectives

Regarding its prospects, Sartorius Stedim Biotech provides organic growth (at exchange rate and perimeter, comparable) of turnover of approximately 7% for financial year 2025, with a range of forecasts of more or less two percentage points (between 5% and 9%) due to volatility always greater than the average.

Oddo BHF specifies that this forecast confirms a “continuation of the resumption of demand and the growth of the bioprocedian market.

In terms of profitability, the management provides for an Ebitda margin of approximately 30 to 31 %, against 28 % the previous year. However, it warns that its turnover and margin forecasts do not yet include the possible effects of customs duties or related attenuation and correction measures.

Cited by Reuters, JP Morgan analysts argue that “the median point of turnover and EBITDA forecasts implies a level of approximately 3% compared to Vara consensus, which again means” that the impact linked to “exchange rate has not been modeled”.

These forecasts which prove to be inferior therefore to expectations can explain the releases on Sartorius Stedim Biotech on the stock market.

The action of the specialist in key technologies for the manufacture of vaccines and drugs drops from 10.2% to 170.95 euros this Tuesday morning around 11:50 am, signing the highest drop in the SBF 120 index.